期刊文献+

南阳牛BoLA-DRA基因的克隆及其在大肠埃希菌中的表达 被引量:2

Cloning and Expression of Nanyang Cattle BoLA-DRA Gene in Escherichia coli
在线阅读 下载PDF
导出
摘要 为克隆南阳牛BoLA-DRA基因,构建原核表达载体并研究该基因在大肠埃希菌中的表达。从南阳牛脾脏组织中提取总RNA,利用RT-PCR方法扩增得到BoLA-DRA基因,将其克隆至pGEM-Teasy克隆载体上,转化感受态细胞DH5α,经测序鉴定后,进一步亚克隆至原核表达载体pGEX-4T-1中,构建出重组表达质粒,经IPTG诱导表达。结果表明,本试验成功克隆了大小为917 bp的BoLA-DRA基因,重组质粒pGEX-4T-DRA在大肠埃希菌中以包涵体形式表达,表达产物经SDS-PAGE和Western blot鉴定大小为54.4 ku,与预期结果一致。为进一步研究该蛋白的功能及制备抗体奠定了基础。 This study aimed to clone Nanyang cattle BoLA-DRA gene, construct recombinant prokaryotic expression vector and to study the gene expression in Escherichia coll. Firstly, BoLA-DRA gene fragment was amplified by RT-PCR after total RNA was extracted from spleen of Nanyang cattle. Following, the BoLA-DRA gene was cloned into the pGEM-T vector and transferred into E. coli DHSa. After sequence a- nalysis, the BoLA-DRA gene was cloned into prokaryotic expression vector pGEX-4T-1 and induced by IPTG (isopropyl β-D-l-thiogalactopyranoside). Results showed that the 917 bp long BoLA-DRA gene was cloned, the fusion protein was obtained successfully,and it existed mostly in the form of inclusion body. I-dentification of expressed products by SDS-PAGE and Western blot showed that the target protein was 54.4 ku which was consistent with the expected results. The results laid a foundation for further studying on the function of the protein and preparation of antibody.
出处 《动物医学进展》 CSCD 北大核心 2010年第6期5-10,共6页 Progress In Veterinary Medicine
基金 国家十一五科技支撑计划项目(2008BADB2B03-03) 国家863计划项目(2008AA101010)
关键词 南阳牛 BoLA-DRA PGEX-4T-1 原核表达 Nanyang cattle BoLA-DRA pGEX-4T-1 prokaryotic expression
  • 相关文献

参考文献3

二级参考文献45

  • 1刘玉洪,花群义,徐自忠,杨云庆,周晓黎,董俊,尹尚莲,许靖逸,高洪.小反刍兽疫病毒H糖蛋白基因原核表达载体的构建及表达[J].中国兽医科学,2006,36(9):692-695. 被引量:11
  • 2Reith W and Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001, 19:331- 373.
  • 3Sospedra M, Obiols G, Babi LF, Tolosa E, Vargas F, Roura-Mir C and Lucas-Martin A, et al. Hyperinducibility of HLA class Ⅱ expression of thyroid follicular cells from Graves' disease. A primary defect? J Immunol 1995, 154:4213- 4222.
  • 4Blanck G. Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunol Immunother 2004, 53:1 -16.
  • 5Osborne A, Zhang H, Yang WM, Seto E and Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol 2001, 21: 6495-6506.
  • 6Boss JM. Regulation of transcription of MHC class Ⅱ genes. Curr Opin Immunol 1997, 9: 107-113.
  • 7Harton JA and Ting JP. Class Ⅱ transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 2000, 20: 6185-6194.
  • 8Osborne A, Tschickardt M and Blanck G. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Res 1997, 25: 5095-5102.
  • 9Zhang H, Shepherd AT, Eason DD, Wei S, Diaz Jl, Djeu JY and Wu GD, et al. Retinoblastoma protein expression leads to reduced Oct-1 DNA-binding activity and enhances interleukin-8 expression. Cell Growth Differ 1999, 10, 457-465.
  • 10Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI and Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. J Biol Chem 2004, 279:28911- 28919.

共引文献7

同被引文献56

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部